Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study Evaluating the Effect of TC-6499 on Gastric Emptying Time in Diabetic Subjects With Gastroparesis

Next Previous
Trial Profile

Study Evaluating the Effect of TC-6499 on Gastric Emptying Time in Diabetic Subjects With Gastroparesis

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TC 6499 (Primary)
  • Indications Diabetic gastroparesis
  • Focus Therapeutic Use
  • Sponsors Targacept

Most Recent Events

  • 16 Apr 2015 According to a Targacept media release, status changed from active, no longer recruiting to completed.
  • 16 Apr 2015 Top-line results published in the Media Release.
  • 16 Apr 2015 Primary endpoint (The change in gastric emptying half-time determined for each treatment relative to placebo after single dose administration of study drug in each arm) has not been met, according to Targacept media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top